Fisher Wallace Laboratories offering is now closed and is no longer accepting investments.
INVEST IN FISHER WALLACE LABORATORIES TODAY!
Medical Devices for Mood and Sleep
$4,666,618.29 Raised
Reasons to Invest
Traction
Over 70,000 patients and 10,000 prescribers in the United States, with over $23.3M in lifetime revenue
Clear Path to FDA Approval
Three clinical trials were submitted to the FDA on March 19, 2021 to support new approval and clearance; over-the-counter approval has been obtained in Europe, and Medicaid has approved the device in Maine (MaineCare)
Previous Crowdfunding Success
Raised over $1M in an oversubscribed Reg CF raise from over 1400+ investors
SUCCESS SINCE OUR LAST RAISE
The FDA defined our approval path on December 19, 2019, requiring Fisher Wallace to conduct three clinical trials (one each for depression, anxiety and insomnia).
- Fisher Wallace submitted clinical trial results to FDA on March 19, 2021 to obtain new FDA Approval and Clearance, as well as expanded insurance coverage.
Fisher Wallace successfully migrated its manufacturing to a high-volume facility that has reduced its cost of goods sold (COGS) by 60%.
THE PROBLEM
Drug therapy provides low to modest efficacy with a high rate of side effects and high cost
THE SOLUTION
FDA regulated wearable treatment - just 20 minutes per day
The Fisher Wallace Stimulator® comfortably stimulates the brain to produce serotonin and modulate brainwave activity. The device has demonstrated a high effectiveness rate and less than a 1% side effect rate (temporary headache or dizziness) in clinical practice. In a depression study conducted at Mount Sinai Beth Israel Hospital in 2015, patients who used a placebo device returned to baseline while patients who used an active (fully functioning) device experienced durable depression symptom reduction.
OUR TRACTION
Over 70,000 patients treated, and multiple clinical trials completed
Fisher Wallace has demonstrated product-market fit by selling over 70,000 medical devices through 10,000 licensed healthcare providers in the United States. The company has executed multiple randomized, controlled clinical trials which have been submitted to the FDA.
* Source
What We do
Symptom reduction in the first week for most patients
Patients may obtain a telemedicine prescription for the device which is then shipped directly to their home. This has been an effective model for treating mental health during the COVID-19 pandemic - and for patients in general who cannot easily access mental health treatment or are resistant to drug or behavioral therapy.
Patients use the device for 20 minutes, one or twice a day, and typically experience symptom reduction within the first week of use. A 392-subject study conducted at a Phoenix House drug and alcohol rehabilitation facility demonstrated that the device increased rehab retention by 50%.
These testimonials may not be representative of the experience of other customers. These testimonials are no guarantee of future performance or success.
THE MARKET
As a result of the pandemic, the rate of depression and anxiety among US adults has skyrocketed to 31
(Source)
- Mental Health is the #1 healthcare cost in the US, greater than cancer, diabetes or heart disease - half of all costs are spent treating depression and anxiety (source)
- 1 in 4 Americans also develop insomnia each year
- Spending is expected to continue growing, especially as demand grows as a result of the pandemic
HOW WE ARE DIFFERENT
The first hardware category to effectively compete with drug therapy for the treatment of depression, anxiety and insomnia
Our affordable medical device is easy to use, causes minimal side effects, may be prescribed remotely and shipped directly to a patient’s home. This offers significant clinical and economic advantages over medication and behavioral therapy while also working well in conjunction with these standards of care (many providers prescribe the Fisher Wallace device in combination with medication and behavioral therapy).
Our goal is to create a new standard of care for the treatment of depression, anxiety and insomnia that is broadly covered by insurance. This is why we have invested in clinical trials and are developing a Version 2.0 device with improved industrial design and an app.
THE BUSINESS MODEL
Expanding from out-of-pocket to broad insurance coverage
THE VISION
To become the world’s leading non-surgical electronics company for the brain - starting with a new standard of care for depression, anxiety and insomnia
Following the completion of our clinical trials, Fisher Wallace has turned its focus to commercializing a Version 2.0 device that will feature improved industrial design, data analytics and digital health services relevant to patients, providers and payers. Our goal is to create a true mental health hardware platform that seamlessly integrates into the rapidly evolving digital health ecosystem.
*This is a computer rendering of a product currently in development
OUR TEAM
Leaders in their field
Kelly Roman (left) and Chip Fisher (right) flank Medal of Honor recipient SFC Petry
WHY INVEST
A clear path to new FDA Approval and Clearance for the treatment of depression, anxiety and insomnia
Obtaining new FDA Approval for one or more indication - depression, anxiety or insomnia - will help establish a new standard of care that can serve millions of patients.
AN OFFERING STATEMENT REGARDING THIS OFFERING HAS BEEN FILED WITH THE SEC. THE SEC HAS QUALIFIED THAT OFFERING STATEMENT, WHICH ONLY MEANS THAT THE COMPANY MAY MAKE SALES OF THE SECURITIES DESCRIBED BY THE OFFERING STATEMENT. IT DOES NOT MEAN THAT THE SEC HAS APPROVED, PASSED UPON THE MERITS OR PASSED UPON THE ACCURACY OR COMPLETENESS OF THE INFORMATION IN THE OFFERING STATEMENT.
THE OFFERING CIRCULAR THAT IS PART OF THAT OFFERING STATEMENT CAN BE FOUND HERE.
THE OFFERING MATERIALS MAY CONTAIN FORWARD-LOOKING STATEMENTS AND INFORMATION RELATING TO, AMONG OTHER THINGS, THE COMPANY, ITS BUSINESS PLAN AND STRATEGY, AND ITS INDUSTRY. THESE FORWARD-LOOKING STATEMENTS ARE BASED ON THE BELIEFS OF, ASSUMPTIONS MADE BY, AND INFORMATION CURRENTLY AVAILABLE TO THE COMPANY’S MANAGEMENT. WHEN USED IN THE OFFERING MATERIALS, THE WORDS “ESTIMATE,” “PROJECT,” “BELIEVE,” “ANTICIPATE,” “INTEND,” “EXPECT” AND SIMILAR EXPRESSIONS ARE INTENDED TO IDENTIFY FORWARD-LOOKING STATEMENTS, WHICH CONSTITUTE FORWARD LOOKING STATEMENTS. THESE STATEMENTS REFLECT MANAGEMENT’S CURRENT VIEWS WITH RESPECT TO FUTURE EVENTS AND ARE SUBJECT TO RISKS AND UNCERTAINTIES THAT COULD CAUSE THE COMPANY’S ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE CONTAINED IN THE FORWARD-LOOKING STATEMENTS. INVESTORS ARE CAUTIONED NOT TO PLACE UNDUE RELIANCE ON THESE FORWARD-LOOKING STATEMENTS, WHICH SPEAK ONLY AS OF THE DATE ON WHICH THEY ARE MADE. THE COMPANY DOES NOT UNDERTAKE ANY OBLIGATION TO REVISE OR UPDATE THESE FORWARD-LOOKING STATEMENTS TO REFLECT EVENTS OR CIRCUMSTANCES AFTER SUCH DATE OR TO REFLECT THE OCCURRENCE OF UNANTICIPATED EVENTS.
WHILE THE COMPANY HAS SIGNED A QUOTATION AGREEMENT TO TRADE THE SECURITIES OFFERED ON STARTENGINE SECONDARY’S NEW ALTERNATIVE TRADING SYSTEM (THE “ATS”), A COMPANY WHICH INTENDS TO BE QUOTED ON THE MARKETPLACE WILL BE SUBJECT TO CERTAIN REQUIREMENTS WHICH THE COMPANY MAY OR MAY NOT BE ABLE TO SATISFY IN A TIMELY MANNER. EVEN IF A COMPANY IS QUALIFIED TO QUOTE ITS SECURITIES ON THE MARKET, THERE IS NO GUARANTEE AN ACTIVE TRADING MARKET FOR THE SECURITIES WILL EVER DEVELOP, OR IF DEVELOPED, BE MAINTAINED. YOU SHOULD ASSUME THAT YOU MAY NOT BE ABLE TO LIQUIDATE YOUR INVESTMENT FOR SOME TIME OR BE ABLE TO PLEDGE THESE SHARES AS COLLATERAL.
ABOUT
HEADQUARTERS
brooklyn
Brooklyn, NY 10028
WEBSITE
View Site
Fisher Wallace is a leading non-surgical electronics company for the brain. Our first product, the Fisher Wallace Stimulator®, is FDA-Cleared to treat depression, anxiety and insomnia. The device has been used by over 70,000 patients and is currently undergoing review by the FDA for new Approval and Clearance.
TEAM
Kelly Roman
Co-Founder & CEO & Director
Charles Fisher
Co-Founder & Chairman & Director
TERMS
Fisher Wallace Laboratories
Overview
PRICE PER SHARE
$6.21
DEADLINE
Oct 27, 2021
VALUATION
$40M
AMOUNT RAISED
$4,666,618.29
Breakdown
MIN INVESTMENT
$496.80
MAX INVESTMENT
$1,999,998.81
MIN NUMBER OF SHARES OFFERED
80
OFFERING TYPE
Equity
ASSET TYPE
COMMON
SHARES OFFERED
Class B Common Stock
MAX NUMBER OF SHARES OFFERED
1,674,718
Maximum Number of Shares Offered subject to adjustment for bonus shares
Company | : | Fisher Wallace, Inc |
Corporate Address | : | brooklyn, Brooklyn, New York 10028 |
Offering Minimum | : | $0.00 |
Offering Maximum | : | $10,399,998.78 |
Minimum Investment Amount(per investor) | : | $496.80 |
Terms
Offering Type | : | Equity |
Security Name | : | Class B Common Stock |
Minimum Number of Shares Offered | : | 0 |
Maximum Number of Shares Offered | : | 1,674,718 |
Price per Share | : | $6.21 |
Pre-Money Valuation | : | $40,000,001.04 |
Time-Based:
Super Early Bird Bonus
Invest within the first 48 hours and receive an additional 10% bonus shares
Early Bird Bonus
Invest within the first week and receive an additional 5% bonus shares
Amount-Based:
$1500+
Free Device
2% Bonus Shares
You will receive a unique coupon code for a free device.
$5000+
Free Device
5% Bonus Shares
You will receive a unique coupon code for a free device.
$10,000+
Free Device
10% Bonus Shares
You will receive a unique coupon code for a free device.
$25,000+
Free Device
15% Bonus Shares
Zoom with CEO
You will receive a unique coupon code for a free device and a 30-minute zoom with our CEO.
The 10% StartEngine Owners’ Bonus
FIsher Wallace Laboratories, Inc. will offer 10% additional bonus shares of Common Stock for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer’s bonus.
This means eligible StartEngine shareholders will receive a 10% bonus for any shares of Class A Common Stock (Non-Voting) which they purchase in this offering. For example, if you buy 100 shares of common shares at $1.00 / share, you will receive and own 110 shares for $100. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.
This 10% Bonus is only valid during the investors' eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.
Investors will only receive a single bonus, which will be the highest bonus rate they are eligible for.
ALL UPDATES
05.09.22
FEATURED IN GEEKWIRE
Dear Investor,
I am pleased to announce that GeekWire, the leading news website for technology and startups, just published the following article featuring Fisher Wallace: "Seattle Police Department testing brain stimulation headband as part of wellness research effort."
“There is a group of people that select into law enforcement that don’t generally think twice about risking their safety for somebody else, but they often have a difficult time taking care of themselves, or accessing self-care,” Loren Atherly, director of performance analytics and research at SPD, told GeekWire.
Best regards,
Our campaign ends in less than 3 weeks.
05.05.22
CAMPAIGN CLOSING SOON
Dear Investors,
Above is a visual engineering status update from Alloy Product Development - our lead engineering partner that previously developed the Beats headphones and Microsoft HoloLens.
We are closing our campaign on May 27th and will not extend it further.
Invest $1500+ to receive a free Version 1 or Version 2 device.
"One of four technologies innovating mental health." - Forbes
Our technology has been cleared by the FDA to treat depression, anxiety and insomnia.
04.29.22
5 STAR REVIEW
One of hundreds of 5 star reviews:
"I'm a careful and somewhat skeptical person--if not meticulous, than at least careful. I'd looked at the Fisher Wallace device a number of times and finally decided to order one in December 2021. I wasn't at my lowest (by any means) then but decided that not only was the time right, but so was the price.I noted on the whiteboard in my office that I commenced using the device Wednesday, 10 December 2021 and found the sessions short and non-disruptive. I had no boundless high hopes but was willing to go through the motions, one way or the other.At roughly the two-week mark, I noticed a definite lightening of the mood that had hung over me (occupied me? possessed me?) for months and months--and which, to be honest, I'd been subject to for roughly 60 years."
by D. B. Robinson, real patient
Individual results may vary.
Invest $1500+ and receive a free Version 1 or Version 2 device.
03.29.22
WE ARE BACK FOR A SHORT TIME!
Dear Investors,
Fisher Wallace is building a new category of prescription wearables to address the $225 billion mental health treatment market in the US.
Today we launched a short campaign to fund for our remaining research initiatives and product development.
Over the past three years, thousands of our customers have joined VC firm SHUFL Capital to fund $8.2 million of our clinical research, product development, and other growth initiatives.
We've generated over $30 million in lifetime revenue, funded five clinical trials (including one currently being conducted by the Seattle Police Department) and are building a new generation of prescription wearable technology for release in 2023.
Invest over the next two days and receive 10% bonus shares as a "Super Early Bird."
Invest $1500+ and receive additional bonus shares and a free Version 2 device.
Thanks for your consideration!
Kelly Roman
Co-Founder & CEO, Fisher Wallace Laboratories
10.26.21
CAPITAL IS POURING IN DURING THE FINAL HOURS!
OFFER CLOSES AT MIDNIGHT!
Dear Investors,
Over the last 48 hours, hundreds of thousands of dollars of investment have poured in - thank you to all of our new investors who have made this one of the most successful raises in StartEngine history! Everyone at Fisher Wallace is excited to move forward with a strong wind at our back as we work hard to transform the mental health industry with our groundbreaking prescription wearable platform. And a special thank you to all of our customers, many of whom have become investors - the journey continues!
Onwards and upwards!
Kelly Roman
Co-Founder and CEO
Fisher Wallace Laboratories, Inc.
Disclaimer: This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. In addition, as described in the Offering Circular, the Company retains the right to continue the offering beyond the Termination Date, in its sole discretion.
10.26.21
HOURS LEFT TO INVEST!
OFFER CLOSES TODAY!
Enjoy the closing update from our Co-Founder & CEO, Kelly Roman:
Invest $1500+ and choose either a Version 1 or Version 2 device as a free perk!
Thanks for your consideration,
Fisher Wallace Laboratories, Inc.
Disclaimer: This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. In addition, as described in the Offering Circular, the Company retains the right to continue the offering beyond the Termination Date, in its sole discretion.
10.25.21
SUPERCHARGING PROGRESS!!
OFFER CLOSES TOMORROW!
Dear Investor,
I received the first crude but beautiful 3D print of our in-development Version 2 from designer Eric Fields over the weekend - a sign of how raising capital on StartEngine has supercharged our progress. More iterations are yet to come, but to see the designs we are working on start to take physical form is very exciting.
We've changed the lives of tens of thousands of patients with Version 1 and intend to change millions more with Version 2. App development is also underway, and our new brand name, icons and guidelines development is nearing completion from Pearlfisher.
It will likely be sometime next year that FDA finalizes its regulatory process, but we are currently cleared to treat depression, anxiety and insomnia - hopefully we will have a new indication (for Generalized Anxiety Disorder) in the near future. I will keep you updated on this front in the months ahead.
As always, if you invest $1500+ you may choose to receive a free Version 1 or Version 2 device.
Thank you for sharing our passion for changing how common mental health conditions are treated in the US and globally!
Best regards,
Kelly Roman
CEO, Fisher Wallace Labs
BTW I'm a collector of Star Wars themed artwork from Suckadelic - you can see a peek of one piece in the background of the above photo, in case you were wondering what that is! ;)
Disclaimer: This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. In addition, as described in the Offering Circular, the Company retains the right to continue the offering beyond the Termination Date, in its sole discretion.
10.21.21
5 DAYS TO GO!
OFFER CLOSES IN 5 DAYS!
We encourage you to watch a patient describe her experience using our Version 1 device. Version 2 is slated to be released next year.
INVEST $1500+ AND RECEIVE A FREE VERSION 1 OR VERSION 2 DEVICE AS A PERK
Thanks for your consideration!
Disclaimer: This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. In addition, as described in the Offering Circular, the Company retains the right to continue the offering beyond the Termination Date, in its sole discretion.
10.20.21
$1500+ INVESTMENT = FREE DEVICE
OFFER CLOSES IN 6 DAYS
"One of four technologies innovating mental health." - Forbes
Invest $1500+ and receive a free device as a perk.
Disclaimer: This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. In addition, as described in the Offering Circular, the Company retains the right to continue the offering beyond the Termination Date, in its sole discretion.
10.19.21
BIG TECH <> MENTAL HEALTH. ONE WEEK TO GO!
OUR CAMPAIGN CLOSES IN A WEEK!
Recent articles in Techcrunch and The Wall Street Journal highlight how Big Tech is beginning to really focus on mental health innovation:
"Apple is reportedly working on ways to help detect and diagnose conditions such as depression, anxiety and cognitive decline using an iPhone. Researchers hope that analysis of data such as mobility, sleep patterns and how people type could spot behaviors associated with those conditions, according to The Wall Street Journal."
Timing is everything as Fisher Wallace moves to build a truly world-class wearable treatment platform in Version 2 - a device that not only tracks, but treats symptoms.
As always, if you invest $1500+ you may choose to receive our Version 1 or Version 2 device for free.
Best regards,
Kelly Roman
Co-Founder and CEO
Fisher Wallace Laboratories, Inc.
Disclaimer: This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. In addition, as described in the Offering Circular, the Company retains the right to continue the offering beyond the Termination Date, in its sole discretion.
REWARDS
$1,500
First Volume Tier
Free Fisher Wallace Device
$2,500
Second Volume Tier
Free Fisher Wallace Device and 2% bonus shares
$5,000
Third Volume Tier
Free Fisher Wallace Device and 3% bonus shares
$10,000
Fourth Volume Tier
Free Fisher Wallace Device and 4% bonus shares
JOIN THE DISCUSSION
0/2500
HOW INVESTING WORKS
Cancel anytime before 48 hours before a rolling close or the offering end date.
WHY STARTENGINE?
REWARDS
We want you to succeed and get the most out of your money by offering rewards and memberships!
SECURE
Your info is your info. We take pride in keeping it that way!
DIVERSE INVESTMENTS
Invest in over 200 start-ups and collectibles!
With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.
With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.
At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.
Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.
StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.
For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.
For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.
Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.
Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.
Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.
